Policy

Latest News

May 16th 2016

A Cost-Effectiveness Analysis of Over-the-Counter Statins

By Christopher Stomberg, PhD, Margaret Albaugh, MA, Saul Shiffman, PhD

This paper estimates the costs and benefits of over-the-counter (OTC) statins using data on statin use and cardiovascular risk, clinical studies of statin safety and efficacy, and an OTC statin use trial.

Sofosbuvir Initial Therapy Abandonment and Manufacturer Coupons in a Commercially Insured Population

ByTaruja D. Karmarkar, MHS,Catherine I. Starner, PharmD,Yang Qiu, MS,Kirsten Tiberg, RPh,Patrick P. Gleason, PharmD

May 3rd 2016

Member cost negatively affects initial medication adherence and manufacturer coupons can decrease member share by up to 98%.

Real-World Outcomes of Ledipasvir/Sofosbuvir in Treatment-Naïve Patients With Hepatitis C

ByZobair M. Younossi, MD, MPH, FACG, AGAF, FAASLD,Haesuk Park, PhD,Stuart C. Gordon, MD,John R. Ferguson,Aijaz Ahmed, MD,Douglas Dieterich, MD,Sammy Saab, MD, MPH

May 3rd 2016

In the treatment of hepatitis C virus, the gap between efficacy and real-world effectiveness narrows with improved tolerability and ease of use.

Coverage for Hepatitis C Drugs in Medicare Part D

ByJeah Kyoungrae Jung, PhD,Roger Feldman, PhD,Chelim Cheong, PhD,Ping Du, MD, PhD,Douglas Leslie, PhD

May 3rd 2016

This study analyzes the current coverage designs for hepatitis C virus drugs by Medicare Part D plans.

Policy

Latest News

Sofosbuvir Initial Therapy Abandonment and Manufacturer Coupons in a Commercially Insured Population

Real-World Outcomes of Ledipasvir/Sofosbuvir in Treatment-Naïve Patients With Hepatitis C

Coverage for Hepatitis C Drugs in Medicare Part D

Experts Share Final Thoughts on Delivering Better Value-Based Care in Oncology

Need for Stakeholder Participation in Developing Payment Models

Is a Single-Payer System the Answer to Our Healthcare Woes?

Impact of Consolidation on the Value of Care Delivery

Limitations of ICER's Value Assessment Framework Tool

Evidence Blocks: Patient Versus Societal Costs

The ASCO Value Framework as a Tool for Shared Decision Making

Using the DrugAbacus Value Calculator

The NCCN Evidence Blocks

Can Oncologists Perceive the Value of a Treatment?

Filling the Data Gaps, Improving Patient Understanding

Data Fragmentation: A Barrier to Value Constructs

Evaluating the Quality of Evidence Used for Developing Value Frameworks

Rightsizing Drug Distribution to Improve Value

How Do Payers Balance Personalized Care With Population Health?

Cost Implications of Oncology Care for the Patient

Value Equation: Do Patients and Oncologists Agree?

Eliminating Data Silos to Benefit the Patient

Understanding the Drug Developer's Perception of Value

Arguing for the Patient as the Consumer of Healthcare

Can Patients Distinguish Volume From Value in Healthcare?

Stakeholders Define Value in Healthcare

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year

Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD

Nutrition in Pregnancy May Shape Metabolic Health After Delivery